Valtrex therapy for Epstein-Barr virus reactivation and upper respiratory symptoms in elite runners

Amanda J Cox, Maree Gleeson, David B Pyne, Philo U Saunders, Robert L Clancy, Peter A. Fricker

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

PURPOSE: The aim of the study was to examine the effectiveness of prophylactic administration of the antiviral agent Valtrex for control of Epstein-Barr virus (EBV) reactivation and upper respiratory symptoms in elite distance runners.

METHODS: Twenty elite male distance runners were randomized into a 4-month double-blind, placebo-controlled cross-over trial. Saliva samples were collected weekly and mucosal immune status assessed by measurement of secretory IgA (SIgA) using an enzyme-linked immunosorbent assay (ELISA). EBV reactivation was monitored at the same time by detection of EBV in saliva using a quantitative real-time polymerase chain reaction. The initial EBV status of the runners was determined by detecting EBV antibodies in serum using an ELISA. Upper respiratory symptoms were recorded using self-reporting illness logs.

RESULTS: There was no evidence of any marked change in maximal oxygen uptake (P = 0.86), training volume (P = 0.30), or mucosal immunity (P = 0.21) over the study period. Valtrex treatment resulted in an 82% reduction in the detectable EBV load in saliva for EBV seropositive runners compared with the placebo treatment (P = 0.04). The incidence of upper respiratory symptoms was not reduced by Valtrex treatment.

CONCLUSIONS: The prophylactic administration of Valtrex reduced EBV reactivation but was not an effective intervention strategy for limiting upper respiratory symptoms in this cohort of elite distance runners. The upper respiratory symptoms in the distance runners could not be directly attributed to infection and may be of a noninfectious inflammatory nature.

Original languageEnglish
Pages (from-to)1104-1110
Number of pages7
JournalMedicine and Science in Sports and Exercise
Volume36
Issue number7
Publication statusPublished - Jul 2004

Fingerprint Dive into the research topics of 'Valtrex therapy for Epstein-Barr virus reactivation and upper respiratory symptoms in elite runners'. Together they form a unique fingerprint.

  • Cite this

    Cox, A. J., Gleeson, M., Pyne, D. B., Saunders, P. U., Clancy, R. L., & Fricker, P. A. (2004). Valtrex therapy for Epstein-Barr virus reactivation and upper respiratory symptoms in elite runners. Medicine and Science in Sports and Exercise, 36(7), 1104-1110.